ecrin-mdr-crcClinical2018IPD Sharing (as of March 2023): NoCarcinomaTriple Negative Breast NeoplasmsGastroEsophageal CancerColorectal Cancer MetastaticNon Small Cell Lung CancerColorectal NeoplasmsCarcinoma, Renal CellTriple Negative Breast CancerBladder CancerRenal Cell CarcinomaBreast NeoplasmsMSI-HCarcinomaTriple Negative Breast NeoplasmsNon Small Cell Lung CancerCarcinoma, Renal CellColorectal Cancer MetastaticColorectal NeoplasmsTriple Negative Breast CancerBladder CancerGastroesophageal CancerRenal Cell CarcinomaBreast NeoplasmsMsi-hInterventionalhttps://newmdr.ecrin.org/Study/2292184CanadaUnited States12PembrolizumabECRIN MDRCompletedfalseA Study of EDP1503 in Patients With Colorectal Cancer, Breast Cancer, and Checkpoint Inhibitor Relapsed TumorsThis study is being conducted to assess the safety, tolerability, and efficacy of EDP1503 alone and in combination with pembrolizumab in patients with advanced metastatic colorectal carcinoma, triple-negative breast cancer, and checkpoint inhibitor relapsed tumors2018-12-152292184NCT03775850